European Medicines Agency Warns of Potential Link Between CAR-T Cell Therapies and Secondary Tumors
CAR-T cell therapies may be directly linked to the development of secondary tumors, particularly those originating from T lymphocytes, according to the European Medicines Agency.
폐암 표적 치료법의 발전: ASCO 2024 회의 주요 내용
폐암 치료에 있어 항체-약물 접합체(ADC), EGFR 돌연변이, ALK 융합 등 다양한 표적 치료법이 발전하고 있으며, 이를 통해 환자의 생존율 향상과 부작용 감소를 기대할 수 있다.
肺がん治療の最新動向 - ASCO 2024での進展
肺がんの標的療法分野で、抗体薬物複合体(ADC)、EGFR変異、ALK融合遺伝子変異などの新しい治療アプローチが注目されている。これらの治療法は患者の予後を大きく改善する可能性がある。
Groundbreaking Advances in Targeted Therapies for Lung Cancer Unveiled at ASCO 2024
Significant progress has been made in the development and application of targeted therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, for the treatment of lung cancer, offering new hope for improved patient outcomes.
Timing of Androgen Receptor Signaling Inhibitor Treatment Shapes the Evolutionary Path to Drug Resistance in Prostate Cancer
The evolutionary path to acquired resistance to androgen receptor signaling inhibition (ARSI) in prostate cancer is dependent on the timing of treatment. In established tumors, resistance occurs through polyclonal adaptation of drug-sensitive clones, while in minimal residual disease, resistance occurs through outgrowth of pre-existing resistant clones.
Racial Disparities in the Incidence and Outcomes of Dermatofibrosarcoma Protuberans, a Rare Cutaneous Sarcoma
Black individuals have a significantly higher incidence of dermatofibrosarcoma protuberans (DFSP), a rare cutaneous soft tissue sarcoma, compared to White individuals. Older age and larger tumor size are associated with poorer overall survival and cancer-specific survival for DFSP patients.
胃食道接合部腺癌の理解、検出、治療
胃食道接合部腺癌の診断と治療において、バイオマーカーの評価、手術前後の治療戦略、再発時の治療アプローチなど、最新の知見が示されている。
Comprehensive Insights into Gastroesophageal Junction Adenocarcinoma: Understanding, Detection, and Innovative Treatment Approaches
Optimizing the management of gastroesophageal junction adenocarcinoma through comprehensive biomarker testing, personalized treatment strategies, and innovative therapeutic approaches.
胃食道接合部腺癌および食道腺癌に対する新しい治療法
胃食道接合部腺癌および食道腺癌の治療において、免疫療法の導入や新しい分子標的薬の開発により、治療成績の向上が期待されている。
Exploring Novel Therapies for Gastroesophageal Junction and Esophageal Adenocarcinoma: Insights from Experts
Experts discuss the evolving landscape of second-line and later-line therapies for gastroesophageal junction and esophageal adenocarcinoma, including the impact of frontline immunotherapy, management of specific molecular subtypes, and emerging targeted agents.
- aiシステムの決定を説明する方法-欧州法の観点からの要件
- ai-결정을-어떻게-설명해야-하는가-유럽법-관점에서-바라본-설명-요구사항
- modeling-the-coevolution-of-coauthorship-and-citation-networks-to-analyze-the-impact-of-key-parameters-on-scientific-impact-indicators
- 論文の引用と共著ネットワークの共進化に基づく科学的インパクト指標への影響分析
- 논문-공저자-관계와-인용-네트워크의-공진화에-기반한-과학적-영향력-지표-분석
- efficient-continual-learning-from-sparsely-labeled-streams-under-constrained-computation
- 大規模部分ラベル付きデータストリームにおける制限された計算量下での継続学習
- 지속적-학습을-위한-효율적인-희소-레이블-데이터-스트림-학습
© 2024 by Linnk AI